Patients with related or unrelated donors for whom the best available donor is: a) mismatched at antigen level for any single class I locus (HLA-A, -B, -C) +/- an additional class I mismatch at the allele level OR mismatched at the allele level for any 2 class I loci (if typed at the molecular level) OR mismatched at the antigen or allele level for class II loci HLA-DRB1 and/or – DQB1; must be matched for at least one DRB1 allele and one DQB1 allele; b) there is a likelihood of rapid disease progression while HLA typing and results of a preliminary search and the donor pool suggests that a 10/10 HLA-A, B, C, DRB1 and DQB1 matched donor will not be found; c) there is no HLA-A, -B or -C one locus allelic mismatched donor available
DONOR: Related or unrelated volunteer donors who are mismatched with the recipient within one of the following limitations:\r\n* Mismatch for one HLA class I antigen with or without an additional mismatch for one HLA-class I allele, but matched for HLA-DRB1 and HLA-DQ, OR\r\n* Mismatched for two HLA class I alleles, but matched for HLA-DRB1 and HLA-DQ, OR\r\n* HLA class I HLA-A, -B, -C allele matched donors allowing for any one or two DRB1 and/or DQB1 antigen allele mismatch
HLA-mismatch at the HLA-A, -B, -C, and - DRB1 loci. Note, HLA-DQ mismatches are permissible
DONOR: HLA mismatched or haploidentical related donors (including 1st degree relatives and half siblings)\r\n* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1; a minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype
DONOR: When more than one donor is available, the donor with the lowest number of HLA allele mismatches will be chosen, unless there is HLA cross-match incompatibility or a medical reason to select otherwise, in which case donor selection is the responsibility of the principal investigator (PI), in consultation with the immunogenetics laboratory; in cases where there is more than one donor with the least degree of mismatch, donors will be selected based on the most favorable combination of (i) HLA compatibility in cross-match testing and (ii) ABO compatibility; will prioritize the lowest number of mismatches in the host-versus-graft (HVG) direction (to potentially minimize graft rejection risk)
Patients with a related donor who is identical for one HLA haplotype
DONOR: Related donors who are identical for one HLA haplotype
Additional Patient Inclusion Criteria for Patients Assigned to Haploidentical BM Arm: Patients must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1 and have available a related haploidentical BM donor with 2, 3, or 4 HLA-mismatches. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must be HLA identical for at least one antigen (using high resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1. Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.
HLA haplo first degree relatives of the patient including biological parents, siblings or half siblings, or children with 2, 3, or 4 mismatches using DNA-based typing. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must be identical at a minimum of one allele (at high resolution DNA-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1.
A minimum genotypic identical match of 4/8 is required, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.
Available related donor who is CMV+ and HLA-haploidentical or better but not fully HLA-matched
Patients must be human leukocyte antigen (HLA) typed at high resolution using deoxyribonucleic acid (DNA) based typing at HLA-A, -B, -C and DRB1 and have an available related haploidentical bone marrow donor with 2, 3, or 4 (out of 8) HLA-mismatches; a unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch
HLA-MISMATCHED UNRELATED DONOR: Unrelated volunteer donors who are mismatched with the recipient within one of the following limitations:\r\n* Mismatch for one HLA class I antigen with or without an additional mismatch for one HLA-class I allele, but matched for HLA-DRB1 and HLA-DQ, OR \r\n* Mismatched for two HLA class I alleles, but matched for HLA-DRB1 and HLA-DQ\r\n* HLA class I HLA-A, -B, -C allele matched donors allowing for any one or two DRB1 and/or DQB1 antigen/allele mismatch
DONOR: Donor preference based on KIR/KIR ligand mismatch\r\n* In addition to HLA determination, KIR genotyping will be performed on potential donors; when more than one potential donor is available, preference will be given to the donor who demonstrates KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient; KIR genotyping and HLA class I typing will be performed in the University of Wisconsin HLA laboratory; if all potential donors show the same degree of KIR/KIR-ligand mismatch, donors will be preferentially selected based on B haplotype KIR gene content
Availability of at least one HLA- haploidentical (i.e. >= 5/10 and =< 8/10 HLA match) related donor (HLA-A, B, C, DR, and DQ loci) who is available to donate CD34+ cells
HLA identical (6/6) related donor available and readily accessible at time of transplantation evaluation
Patient must have available one or more potential first (biologic mother, sister, half-sister, or daughter) or second-degree related female donor; mothers and daughters have a 100% chance of being haploidentical matches, sisters a 75% chance of being matched or haploidentical, and second degree relatives have a 50% chance of being haploidentical matches; the donor and recipient must be HLA identical for at least one antigen at HLA-A, -B, -C and HLA-DRB1
Patients and selected donor must be HLA typed at high resolution using deoxyribonucleic acid (DNA) based typing at the following HLA-loci: HLA-A, -B, -C and DRB1; donors must be HLA-haploidentical relatives including, but not limited to, children, siblings, or parents, defined as having a shared HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1
DONOR: Partially HLA-mismatched relative (allele level matched at 4 to 7 of 8 HLA loci: -A, -B, -C, and -DRB1)
DONOR: \r\n* HLA haploidentical relative of the patient; a unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch; the donor and recipient must be identical at least one allele (high resolution DNA-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 \r\n* If patient over age 25 years, may use HLA identical sibling donor\r\n* If patient has inherited bone marrow failure syndrome (IBMFS) and clear evidence of same disorder in potential related donors, unrelated donor may be used; unrelated donor must be a 10/10 match using HLA-A, -B, -C, DRB1, and DPB1; unrelated donor may also be used in case of donor specific antibodies to related donors or other clinical causes of unsuitable related donors
DONOR: HLA-haploidentical donor/recipient match by molecular typing at the HLA-A, HLA-B and HLA-DRB1 loci
DONOR: In addition to HLA determination, KIR genotyping will be performed on potential donors; preference will be given to donors who demonstrate KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient; KIR genotyping and HLA class I typing will be performed in the University of Wisconsin HLA laboratory; the following KIR genes and corresponding HLA class I ligands will be analyzed:\r\n* KIR Gene; HLA Class I Ligand\r\n* KIR3DLI; HLA Bw4\r\n* KIR2DL1; HLA C^LYS80\r\n* KIR2DL2/3; HLA C^ASN80\r\nIf all potential donors show the same degree of KIR/KIR-ligand mismatch, donors will be preferentially selected based on B haplotype KIR gene content according to the method described by Cooley et al., using the donor KIR B-content group calculator
DONOR: Donor with full haplotype HLA-mismatch will be preferred (4 out of 8 HLA match) to maximize graft-versus-leukemia (GVL)
Cord blood units available through National Marrow Donor Program (NMDP) with the following minimal criteria;\r\n* HLA Match: 4/6 or better match (HLA A, B, DRB1)\r\n* Cell dose: minimum of 2 x 10^7 total number of nucleated cells (TNC)/kg pre thaw
There are CMVpp65-specific T-cells available in appropriate doses in the MSKCC Adoptive Immune T-cell Therapy Bank that are matched with the patient for 1 HLA allele and that exhibit CMVpp65-specific cytotoxic activity that is restricted by an HLA allele shared by the patient
DONOR: HLA matching criteria
HAPLOIDENTICAL RELATED DONOR: A haploidentical donor is a related donor that shares one haplotype in common with the recipient such that HLA compatibility will be a minimum of 5 out of 10 HLA loci matched; the HLA loci to be tested will be HLA A, B, Cw, DRB1, and DQB1; a minimum number of mismatches is desirable; however if several options are available the selection of a donor will be based on the loci where the mismatch occurs and the relative importance of its potential immunological function; donor-recipient pairs will initially be typed molecularly to provide a low resolution typing (antigen-level) to aid in the selection of the potential donor; upon review of the familial inheritance pattern, a qualified HLA staff member will review haplotype inheritance; high resolution (allele level) typing will be performed; final selection of a donor will be in consultation with National Cancer Institute (NCI) physicians and qualified HLA personnel; haploidentical related donors for pediatric recipients must be 6 years of age or older; if more than one haploidentical related donor is available, we will evaluate each donor individually according to overall health, ABO matching, cytomegalovirus (CMV), etc. to select the donor
Presence of a suitable first-degree related, human leukocyte antigen (HLA)-haploidentical or HLA-matched bone marrow donor\r\n* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1; a minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype
Availability of a related or unrelated donor with a 7/8 or 8/8 match for HLA-A, B, C, and DRB1.
Patients with acquired immunodeficiency syndrome (AIDS) developing EBV lymphomas or lymphoproliferative diseases as a consequence of the profound acquired immunodeficiency induced by human immunodeficiency virus (HIV); for such patients, EBV specific T-cells from third party seropositive donors who are HLA compatible in 1) at least 2 HLA antigens and 2) one restricted allele shared by the patient will be used; selection of T cells known to be restricted by an HLA allele shared by the patient will be given priority
Patients must have an HLA-identical related or HLA-matched unrelated donor
Absence of a suitable partially HLA-mismatched (haploidentical), first-degree related donor; Note: determination of matching is based on allele or allele group level typing; to be considered haploidentical, the donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, -B, -Cw, -DRB1, and –DQB1; a minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor recipient share one HLA haplotype; donors who are homozygous for the CCR5delta32 polymorphism are given preference
DONOR: The donor and recipient must be identical at least 5 HLA alleles based on high resolution typing of HLA-A, -B, -Cw, -DRB1, and -DQB1, with at least one allele matched for a HLA class I gene (HLA-A, -B, or -Cw) and at least one allele matched for a class II gene (HLA-DRB1 or -DQB1)
HAPLOIDENTICAL RELATED DONOR: A haploidentical donor that shares one haplotype in common with the recipient such that HLA compatibility will be a minimum of 5 out of 10 HLA loci matched; the HLA loci to be tested will be HLA A, B, Cw, DRB1, and DQB1; a minimum number of mismatches is desirable; however if several options are available the selection of a donor will be based on the loci where the mismatch occurs and the relative importance of its potential immunological function; donor-recipient pairs will initially be typed molecularly to provide a low resolution typing (antigen-level) to aid in the selection of the potential donor; upon review of the familial inheritance pattern, a qualified HLA staff member will review haplotype inheritance; high resolution (allele-level) typing will be performed; final selection of a donor will be in consultation with National Cancer Institute (NCI) physicians and qualified HLA personnel; if more than one haploidentical related donor is available, we will evaluate each donor individually according to overall health, ABO matching, cytomegalovirus (CMV), etc. to select the donor
DONOR: Related donors who are genotypically identical for one HLA haplotype and who may be mismatched at the HLA-A, -B, -C or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or -C allele mismatches
Have a related or unrelated human lymphocyte antigen (HLA) -identical donor or one antigen/allele mismatched in HLA-A, B, C or DRB1
Recipients with unrelated donor matched at the HLA A, B, DRBI loci, or if < 35 years mismatched at a single HLA A or B, or DRBI locus
DONOR: When more than one HLA-haploidentical donor is available, the donor with the lowest number of HLA allele mismatches will be chosen, unless there is HLA cross-match incompatibility, in which case donor selection is the responsibility of the project investigator (PI), in consultation with the immunogenetics laboratory; in cases where there is more than one donor with the least degree of mismatch, donors will be selected based on the most favorable combination of (i) HLA compatibility in cross-match testing and (ii) ABO compatibility:
Available HLA-genotypically identical related donor
No existing HLA-identical related donor is available
Related donors that are matched at HLA 7-8/8 loci (HLA A, B, C, and DRB1 loci) by intermediate resolution
Unrelated donors that are matched at HLA 8/8 (HLA A, B, C, and DRB1 loci); 1 allele/antigen mismatch at HLA-A, -B, -C, or DRB1 may be considered if no other suitable donor available
Inclusion Criteria:\n\n          1. Signed informed consent\n\n          2. Patients with one of the life-threatening hematological malignancies:\n\n               -  Acute lymphocytic leukemia (ALL) in CR1 with high-risk features including adverse\n                  cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements;\n                  greater than 1 cycle to achiever remission or with persistent MRD; ALL in second\n                  or greater remission with or without MRD. Acute myeloid leukemia (AML) in CR1\n                  with high-risk features defined as: Greater than 1 cycle of induction therapy\n                  required to achieve remission; Preceding myelodysplastic syndrome (MDS) or\n                  myeloproliferative disease; Presence of FLT3 mutations or internal tandem\n                  duplications; FAB M6 or M7 classification; Adverse cytogenetics, -5, del 5q, -7,\n                  del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 [> 3 abnormalities];\n\n               -  AML in second or greater remission, primary induction failure and patients with\n                  relapsed disease;\n\n               -  Advanced chronic myeloid leukemia (CML) who have progressed to blast phase or\n                  accelerated phase and are in need of a transplant and do not have an HLA matched\n                  donor;\n\n               -  MDS with IPSS intermediate-2 or higher or therapy-related MDS.Hodgkin lymphoma or\n                  Non-Hodgkin lymphoma (NHL): relapsed disease where remission duration is less\n                  than 1 year, relapse after previous autologous transplant, or failure to achieve\n                  CR with chemotherapy.\n\n          3. Age ? 18 years and ? 65 years\n\n          4. Deemed eligible for allogeneic stem cell transplantation\n\n          5. Lack of suitable conventional donor (i.e. 8/8 related or unrelated donor) or presence\n             of rapidly progressive disease not permitting time to identify an unrelated donor\n\n          6. HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw,\n             and DRBl loci\n\n               -  A minimum genotypic identical haplotype match of 4/8 is required\n\n               -  The donor and recipient must be identical, as determined by high resolution\n                  typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B,\n                  HLA-Cw, and HLA- DRB1\n\n          7. Subjects with adequate organs function as measured by:\n\n               -  Cardiac: Left ventricular ejection fraction at rest must be >45%\n\n               -  Pulmonary: FEV 1, FVC, DLCO (diffusion capacity) > 50% predicted (corrected for\n                  hemoglobin); or O2 saturation > 92% on room air\n\n               -  Hepatic: Direct bilirubin ? 3 x upper limit of normal (ULN), or AST/ALT ? 5 x ULN\n\n               -  Renal: Serum creatinine within normal range for age or creatinine clearance, or\n                  with a recommended GFR ? 50 mL/min/1.73m2\n\n          8. Performance status: Karnofsky ? 80%\n\n        Exclusion Criteria:\n\n        Subjects meeting the following criteria are NOT eligible for the study:\n\n          1. HLA 8/8 allele matched (HLA-A,-B,-Cw,-DRBl) related or unrelated donor able to donate;\n\n          2. Autologous hematopoietic stem cell transplant ? 3 months prior to enrollment;\n\n          3. Prior allogeneic transplantation;\n\n          4. Active CNS involvement by malignant cells (less than 2 months from the conditioning);\n\n          5. Current uncontrolled bacterial, viral or fungal infection (currently taking medication\n             with evidence of progression of clinical symptoms or radiologic findings); the PI is\n             the final arbiter of this criterion;\n\n          6. Positive HIV serology or viral RNA (? Grade III per CTCAE criteria);\n\n          7. Pregnancy (positive serum or urine ?HCG test) or breast-feeding;\n\n          8. Fertile men or women unwilling to use effective forms of birth control or abstinence\n             for a year after transplantation;\n\n          9. Bovine product allergy.\n\n         10. Severe obesity (patient's weight is >/= 1.5x the donor weight).
DONOR: Institutional guidelines for HLA-match may be followed as long as the minimum criteria for HLA-matching as above are met
Match-specific criteria:\r\n* HLA mismatched or haploidentical related donors: The donor and recipient must be haploidentical at a minimum of one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1\r\n* Donor-specific anti-HLA antibody testing requirement: Testing for antibodies targeting donor specific HLA antigens at HLA-A, B, C, DRB1, DQ and DP will be completed as per institutional standards\r\n* When more than one donor is available, the donor with the lowest number of HLA allele mismatches will be chosen, unless there is an HLA cross-match incompatibility or a medical reason to select otherwise, in which case donor selection is the responsibility of the principal investigator (PI); in cases where there is more than one donor with the least degree of mismatch, donors will be selected based on the most favorable combination of the factors below
Myelodysplastic syndrome (MDS) with < 5% blasts by morphology and meets at least one of the following:\r\n* Received intensive induction chemotherapy (i.e. 7+3 or mitoxantrone, etoposide, and cytarabine [MEC]) OR\r\n* Progression after 4 cycles of hypomethylating agents \r\n** The donor and recipient must be human leukocyte antigen (HLA) identical for at least one haplotype (using high resolution deoxyribonucleic acid [DNA] based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1
DONORS: HLA-haploidentical related donor (aged 18 to 75 years) where donor and recipient must be HLA identical for at least one haplotype (using high resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1
DONOR: Appropriate HLA-match to patient
Availability of a human leukocyte antigen (HLA) matched (6/6) sibling donor or 8/8 matched unrelated donor; Donors with mismatch at HLA-A, HLA-B, HLA-C, and HLA-DR will be reviewed by matched unrelated donor (MUD) committee and allowed if their mismatch with the recipient does not require additional GVHD prophylaxis (other than tacrolimus and sirolimus), donors with mismatch at HLA-DQ or HLA-DPB are eligible; donor evaluation according to City of Hope (COH) standard operating procedure (SOP)
Patients must have a first-degree related donor or half-sibling who is at minimum HLA haploidentical to be enrolled; the donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1; a minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype
The donor and recipient must be identical, as determined by high resolution typing, on at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
HLA-identical related or HLA-matched unrelated donor available
Partially HLA-mismatched unrelated donor: HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, -C, and -DRB1 loci; a minimum match of 4/8 at HLA-A, -B, -C, and -DRB1 is required
Have 8/8 allele-level, related or unrelated, medically cleared HSC donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1
Presence of a suitable related, HLA-haploidentical or HLA-matched stem cell donor\r\n* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1; a minimum match of 5/10 is therefore required for related donors, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype
Donors must be either:\r\n* HLA-haploidentical or HLA-identical relatives of the patient based on allele or allele group level typing
DONOR: Haploidentical 1st-degree relative as defined by 3/6 or 4/6 HLA-matched at HLA -A, -B, or –DRB1 who is 18-70 years of age
HLA-Mismatched Related and Unrelated Donors: Patients who do not have an HLA-matched donor but have a related or unrelated donor who have one antigen or one allele mismatch at the HLA A, B, C, DRB1 or DQB1 loci; or who have two mismatches, at HLA-DQB1 and at one other locus will be eligible for entry on this protocol
Available related donor that is at least an allele level haplotype-match at human leukocyte antigen (HLA)- A, B, C, DRB1 and DPB1 loci (DPB1 matching according to the “permissive – non-permissive” dichotomy as stated by University of Wisconsin [UW] Histocompatibility Laboratory); a minimum match of 5/10 loci is required; an unrelated donor search is not required for a patient to be eligible for this protocol
HAPLO-IDENTICAL DONOR: A HLA-haplo-identical related donor will be selected as available as per standard MSKCC adult bone marrow transplantation (BMT) guidelines; mismatched family members who are matched at more than 5 of 10 HLA-loci are permitted; factors to be taken into account when selecting a haplo-identical donor will include donor age, weight, health status and comorbidities, compliance, venous access, recipient donor specific HLA-antibody status, and natural killer (NK) cell alloreactivity
Donor/Recipient HLA Matching:
HLA-mismatched related and unrelated donors: \r\n* Patients who do not have an HLA-matched donor but have a related or unrelated donor who have one antigen or one allele mismatch at the HLA A, B, C, DRB1 or DQB1 loci; or who have two mismatches, at HLA-DQB1 and at one other locus, will be eligible for entry on this protocol
DONOR: Related, HLA-haploidentical donors who are identical for one HLA haplotype and mismatched for any number of HLA-A, -B, -C, DRB1 or DQB1 loci of the unshared haplotype
Patients must have a related donor who is identical for one human leukocyte antigen (HLA) haplotype and mismatched at the HLA-A, -B or class II, DR beta 1 (DRB1) loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches
DONOR: Related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B, or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B, or DRB1 mismatches
RELATED DONORS: When more than one potential donor exists, priority should be given to donors based on HLA identity > cytomegalovirus (CMV) seronegativity > ABO compatibility > sex matching\r\n* Donor who is HLA phenotypically or genotypically identical at the allele level at HLA-A, -B, -C, -DRB1, and -DQB1\r\n* Must consent to G-CSF administration and leukapheresis; \r\n* Must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian);\r\n* Only G-CSF mobilized PBMC only will be permitted as a hematopoietic stem cell (HSC) source on this protocol
Available human leukocyte antigen (HLA)-matched or -haploidentical, living related donor who is willing to donate bone marrow and part of liver; the donor and recipient must be HLA identical for at least one allele (using high resolution deoxyribonucleic acid [DNA] based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C and HLA-DRB1; fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype
Recipient of a first renal allograft from a human leukocyte antigen (HLA)-haploidentical, living related donor; the donor and recipient must be HLA identical for at least one allele (using high resolution deoxyribonucleic acid [DNA] based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1; fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype
DONOR: HLA-haploidentical, first-degree relatives or half-siblings of the recipient participant at the allele or allele group; the donor and recipient must be HLA identical for at least one allele (using high resolution DNA based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C and HLA-DRB1; fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype
Presence of a suitable first-degree related, HLA-haploidentical or HLA-matched bone marrow donor;\r\n* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1; a minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype
DONOR: Donors must be HLA-haploidentical or HLA-identical, first-degree relatives of the patient based on allele or allele group level typing; half-siblings are not permitted
Positive patient anti-donor lymphocyte crossmatch in HLA-A or B mismatched transplants; the definition of match is in Section 2.2.1; the crossmatch would only apply to mismatches at HLA-A or B, not DRB1 or HLA-C
Related donor of T cells must be at least partially human leukocyte antigen (HLA) compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this)\r\n* Donor selection priority: The original donor will be the first choice as source of T cells; If the original donor is unavailable for donation of peripheral mononuclear cells or does not meet all donor eligibility criteria, alternative related donors will be selected, with preference for those who have full HLA matching in 6/6 loci over those with partial HLA matching (>= 3/6 HLA loci)
Presence of a suitable related, HLA?haploidentical or HLA?matched stem cell donor or unrelated matched donor\r\n* The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA?A, HLA?B, HLA?Cw, HLA?DRB1, and HLA?DQB1; a minimum match of 5/10 is therefore required for related donors, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype; unrelated donors will be 10/10
DONOR: donors must be either:\r\n* HLA?haploidentical or HLA?identical relatives of the patient based on allele or allele group level typing\r\n* Unrelated donor who is a 10/10 match to the recipient
If a haploidentical donor is considered, parents, children, full siblings and in selected cases, extended family, will have high resolution typing at the MCC HLA laboratory; a familiar haploidentical donor is chosen among those who share at least one HLA-A, B, C, DRB1 and DQB1 haplotype with the patient
UNRELATED DONOR: an HLA 7/8 or 8/8 HLA A, B and C (class I) and HLA DRB1 (class II) alleles, or 9/10 or 10/10 HLA A, B and C (class I) and HLA DRB1 and DQB1 (class II) alleles will be required for study entry
Patient plans on receiving stem cells from a donor who has a 3 or more HLA mismatch
Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci of the unshared haplotype
HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw, and DRBl, and loci. A minimum match of 5/10 is required. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, and HLA- DRB1.
